Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENLV Stock Forecast 2026-2027
$0.77
Current Price
$185.61M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ENLV Price Targets
+2,497.4%
To High Target of $20.00
+2,497.4%
To Median Target of $20.00
+2,497.4%
To Low Target of $20.00
ENLV Price Momentum
-9.4%
1 Week Change
-19.8%
1 Month Change
-24.5%
1 Year Change
+10.0%
Year-to-Date Change
-63.3%
From 52W High of $2.10
+16.7%
From 52W Low of $0.66
📊 TOP ANALYST CALLS
Did ENLV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enlivex is one of their latest high-conviction picks.
Latest ENLV Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ENLV has a bullish consensus with a median price target of $20.00 (ranging from $20.00 to $20.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.77, the median forecast implies a 2,497.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 2,497.4% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 2,497.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENLV Analyst Ratings
1
Buy
0
Hold
0
Sell
ENLV Price Target Range
Low
$20.00
Average
$20.00
High
$20.00
Current: $0.77
Latest ENLV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENLV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $20.00 |
| Jan 12, 2026 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $13.00 |
| Nov 24, 2025 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $N/A |
| Oct 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 26, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 2, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Aug 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Aug 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Jul 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Jul 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Apr 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Apr 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Mar 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Feb 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Dec 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Dec 3, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Nov 14, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $13.00 |
| Sep 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $6.00 |
Enlivex Therapeutics Ltd (ENLV) Competitors
The following stocks are similar to Enlivex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enlivex Therapeutics Ltd (ENLV) Financial Data
Enlivex Therapeutics Ltd has a market capitalization of $185.61M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +126.2%.
Valuation Metrics
Market Cap
$185.61M
Enterprise Value
$192.62M
P/E Ratio
0.0x
PEG Ratio
-1.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+3.1%
Current Ratio
193.2x
Debt/Equity
0.0x
ROE
+126.2%
ROA
-0.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enlivex Therapeutics Ltd (ENLV) Business Model
About Enlivex Therapeutics Ltd
What They Do
Developing innovative immunotherapy solutions.
Business Model
The company operates a clinical-stage business model centered on its proprietary product, Allocetra, which is a universal cell therapy designed to reprogram macrophages to restore immune balance. It targets high-demand areas such as inflammatory diseases, sepsis, and solid tumors, generating revenue through clinical programs aimed at addressing significant unmet medical needs in multi-billion-dollar markets.
Additional Information
Enlivex Therapeutics was founded in 2005 and is headquartered in Ness Ziona, Israel. It employs a scalable manufacturing process for its therapies and maintains a favorable safety profile in clinical settings. Additionally, the company is involved in a treasury strategy that includes exposure to prediction markets, blending biotechnology with digital asset investments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
34
CEO
Country
Israel
IPO Year
N/A
Website
www.enlivex.comEnlivex Therapeutics Ltd (ENLV) Latest News & Analysis
Latest News
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
10 days ago
Quick Summary
Enlivex's primary digital treasury asset is now listed on a major global cryptocurrency exchange, enhancing market access and secondary liquidity.
Why It Matters
The listing enhances Enlivex's visibility and liquidity, potentially increasing demand and value for its digital treasury asset, influencing investor sentiment and market dynamics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Ltd. announced a significant increase in its RAIN holdings to 78.8 billion tokens, valued at $567 million, as part of its prediction markets treasury strategy.
Why It Matters
Enlivex's substantial increase in RAIN holdings to $567 million signals strong financial health and strategic positioning, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
17 days ago
Quick Summary
Enlivex Ltd. (Nasdaq: ENLV) will present two poster abstracts at the OARSI 2026 World Congress on Osteoarthritis from April 23-26 in West Palm Beach, Florida.
Why It Matters
Enlivex's presentation at a prominent osteoarthritis conference could enhance its visibility, attract partnerships, and potentially boost stock value through increased investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Ltd. (Nasdaq: ENLV) announced CTA approval from the Danish Medicines Agency for a Phase 2b trial of Allocetra™, targeting moderate-to-severe knee osteoarthritis.
Why It Matters
Approval of the clinical trial for Allocetra™ enhances Enlivex's growth potential and market position in the immunotherapy sector, potentially driving stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Ltd. announced the launch of ENLVon, a tokenized representation of its ordinary shares on Ondo Finance's Global Markets platform.
Why It Matters
The launch of ENLVon tokenizes Enlivex shares, enhancing liquidity and access for investors, potentially increasing market interest and driving share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enlivex Ltd. reported financial results for 2025, highlighting earnings driven by appreciation in Treasury and related assets. The report was issued on March 25, 2026.
Why It Matters
Enlivex's earnings growth from Treasury asset appreciation signals financial health, potentially boosting investor confidence and affecting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ENLV Stock
What is Enlivex Therapeutics Ltd's (ENLV) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Enlivex Therapeutics Ltd (ENLV) has a median price target of $20.00. The highest price target is $20.00 and the lowest is $20.00.
Is ENLV stock a good investment in 2026?
According to current analyst ratings, ENLV has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENLV stock?
Wall Street analysts predict ENLV stock could reach $20.00 in the next 12 months. This represents a 2,497.4% increase from the current price of $0.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enlivex Therapeutics Ltd's business model?
The company operates a clinical-stage business model centered on its proprietary product, Allocetra, which is a universal cell therapy designed to reprogram macrophages to restore immune balance. It targets high-demand areas such as inflammatory diseases, sepsis, and solid tumors, generating revenue through clinical programs aimed at addressing significant unmet medical needs in multi-billion-dollar markets.
What is the highest forecasted price for ENLV Enlivex Therapeutics Ltd?
The highest price target for ENLV is $20.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 2,497.4% increase from the current price of $0.77.
What is the lowest forecasted price for ENLV Enlivex Therapeutics Ltd?
The lowest price target for ENLV is $20.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 2,497.4% increase from the current price of $0.77.
What is the overall ENLV consensus from analysts for Enlivex Therapeutics Ltd?
The overall analyst consensus for ENLV is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ENLV stock price projections?
Stock price projections, including those for Enlivex Therapeutics Ltd, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 10, 2026 7:12 PM UTC